PRESS RELEASE For immediate release Devonian Health Group Reports Third Quarter 2025 Financial Results Third quarter revenues increased 36% compared to 3Q24 Third quarter net loss of $0.032 per share Québec, QUÉBEC, June 26, 2025 – Devonian Health Group Inc....
Press Releases
DEVONIAN APPOINTS NEW OFFICERS AND ANNOUNCES GRANT OF STOCK OPTIONS
PRESS RELEASE For immediate release QUÉBEC, Québec, June 9, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
PRESS RELEASE For immediate release QUÉBEC, April 28, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application for reinstatement of trading of the...
Devonian Health Group Reports Second Quarter 2025 Financial Results
PRESS RELEASE For immediate release Second quarter revenue increased 275% year over year Second quarter net loss of $0.001 per share Debt repaid in full Québec, QUÉBEC, April 15, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB:...
Devonian Health Group Reports Cease Trade Order
PRESS RELEASE For immediate release QUEBEC CITY--(BUSINESS WIRE)--April 14, 2025--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announces that the Autorité des Marchés Financiers (the “AMF”) has issued a failure to file cease...
Devonian Reports Delay of Financial Reporting
PRESS RELEASE For immediate release Devonian Reports Delay of Financial Reporting QUÉBEC, April 1st, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to...
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
PRESS RELEASE For immediate release Devonian Reports Results of its Annual General and Special Meeting of Shareholders Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, March 24, 2025 – Devonian Health Group Inc....
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an antifibrotic agent
QUÉBEC, Québec, February 19, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new patent application...
DEVONIAN ANNOUNCES POSITIVE IN VIVO RESULTS OF THYKAMINE™ ON GENE EXPRESSION ASSOCIATED WITH FIBROSIS
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced positive results from a gene analysis conducted as part of in vivo study in STAM™ mouse model.
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) QUÉBEC, Québec, February 13, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”)...